Ranbaxy Provisions For U.S. Settlement But Reveals Little
This article was originally published in PharmAsia News
Executive Summary
Indian drug maker Ranbaxy turned a loss in the first quarter of the 2015 financial year, mainly impacted by a $40 million provision it made for a settlement with the U.S. government. But no more disclosures about the issue have been released so far.